Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH Chromium, Antioxidant Diabetes Program Announcements Issued

This article was originally published in The Tan Sheet

Executive Summary

The National Institutes of Health has established two new programs to fund studies on the benefits of chromium and antioxidants in diabetic subjects.

You may also be interested in...



More Chromium Research Needed To Set RDA, FNB Report Concludes

Further research on the benefits of chromium supplementation is needed before a Recommended Dietary Allowance for the mineral can be established, the Institute of Medicine's Food & Nutrition Board states in its Dietary Reference Intakes report on micronutrients released Jan. 9.

Botanical/Drug Interactions To Be Studied By NCCAM

A project concept calling for the study of botanical/ drug interactions in animal models through Phase I/II clinical studies was approved by the National Center for Complementary & Alternative Medicine's advisory council at a May 8 meeting in Rockville, Md.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel